{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PB1046+Injection",
    "query": {
      "intervention": "PB1046 Injection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T03:57:07.875Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02808585",
      "title": "Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "PB1046 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2016-06",
      "completion_date": "2017-12-06",
      "has_results": true,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-09-06T03:57:07.875Z",
      "location_count": 5,
      "location_summary": "Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "McKinney",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02808585"
    },
    {
      "nct_id": "NCT01523067",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Vasomera (PB1046)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 68,
      "start_date": "2012-01",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-09-06T03:57:07.875Z",
      "location_count": 5,
      "location_summary": "Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01523067"
    },
    {
      "nct_id": "NCT03315507",
      "title": "A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "PB1046 Subcutaneous Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-10-20",
      "completion_date": "2019-08-08",
      "has_results": false,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-09-06T03:57:07.875Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03315507"
    },
    {
      "nct_id": "NCT03795428",
      "title": "Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046) Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-04-10",
      "completion_date": "2022-01-11",
      "has_results": false,
      "last_update_posted_date": "2022-02-22",
      "last_synced_at": "2026-09-06T03:57:07.875Z",
      "location_count": 16,
      "location_summary": "La Jolla, California • Sacramento, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03795428"
    },
    {
      "nct_id": "NCT03556020",
      "title": "Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 35,
      "start_date": "2018-07-15",
      "completion_date": "2022-01-07",
      "has_results": false,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-09-06T03:57:07.875Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03556020"
    },
    {
      "nct_id": "NCT04433546",
      "title": "Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome",
        "Coronavirus",
        "Hypoxic Respiratory Failure",
        "Hypoxemic Respiratory Failure",
        "Respiratory Complication",
        "Respiratory Insufficiency",
        "Cardiac Dysfunction",
        "Pneumonia",
        "Pulmonary Edema",
        "Pulmonary Inflammation",
        "Respiratory Failure",
        "Cytokine Storm",
        "COVID 19",
        "SARS-CoV-2",
        "Cardiac Event",
        "Cardiac Complication",
        "Cardiac Failure",
        "Cardiac Infarct"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046)",
          "type": "DRUG"
        },
        {
          "name": "Low Dose (10 mg) Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 54,
      "start_date": "2020-07-15",
      "completion_date": "2020-12-02",
      "has_results": false,
      "last_update_posted_date": "2020-12-11",
      "last_synced_at": "2026-09-06T03:57:07.875Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433546"
    }
  ]
}